RU2653054C2 - Замещенные соединения пиридин азолопиримидин-5-(6н)-она - Google Patents

Замещенные соединения пиридин азолопиримидин-5-(6н)-она Download PDF

Info

Publication number
RU2653054C2
RU2653054C2 RU2015100213A RU2015100213A RU2653054C2 RU 2653054 C2 RU2653054 C2 RU 2653054C2 RU 2015100213 A RU2015100213 A RU 2015100213A RU 2015100213 A RU2015100213 A RU 2015100213A RU 2653054 C2 RU2653054 C2 RU 2653054C2
Authority
RU
Russia
Prior art keywords
triazolo
pyrido
methyl
pyrimidin
methoxybenzyl
Prior art date
Application number
RU2015100213A
Other languages
English (en)
Russian (ru)
Other versions
RU2015100213A (ru
Inventor
Эми АЛЛАН
Брайан БРАНСТЕТТЕР
Брайан Дик
Майкл И. ВАЙНХАУС
Лоран ГОМЕЗ
Тэми Джо МЭРРОН
Марко ПИТЕРС
Original Assignee
Дарт Нейросайенс (Кайман) Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дарт Нейросайенс (Кайман) Лтд filed Critical Дарт Нейросайенс (Кайман) Лтд
Publication of RU2015100213A publication Critical patent/RU2015100213A/ru
Application granted granted Critical
Publication of RU2653054C2 publication Critical patent/RU2653054C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
RU2015100213A 2012-06-18 2013-06-18 Замещенные соединения пиридин азолопиримидин-5-(6н)-она RU2653054C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261661091P 2012-06-18 2012-06-18
US61/661,091 2012-06-18
PCT/US2013/046415 WO2013192229A1 (en) 2012-06-18 2013-06-18 Substituted pyridine azolopyrimidine - 5 - (6h) - one compounds

Publications (2)

Publication Number Publication Date
RU2015100213A RU2015100213A (ru) 2016-08-10
RU2653054C2 true RU2653054C2 (ru) 2018-05-07

Family

ID=49756458

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2015100213A RU2653054C2 (ru) 2012-06-18 2013-06-18 Замещенные соединения пиридин азолопиримидин-5-(6н)-она
RU2015100209A RU2659779C2 (ru) 2012-06-18 2013-06-18 Замещенные соединения тиофен- и фуран-конденсированного азолопиримидин-5-(6н)-она

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2015100209A RU2659779C2 (ru) 2012-06-18 2013-06-18 Замещенные соединения тиофен- и фуран-конденсированного азолопиримидин-5-(6н)-она

Country Status (17)

Country Link
US (7) US9175010B2 (enExample)
EP (3) EP2861603B1 (enExample)
JP (2) JP6240180B2 (enExample)
KR (2) KR102191816B1 (enExample)
CN (2) CN104583217B (enExample)
AU (3) AU2013277294C1 (enExample)
BR (2) BR112014031731B1 (enExample)
CA (2) CA2877149C (enExample)
DK (2) DK2861603T3 (enExample)
ES (2) ES2904267T3 (enExample)
IL (2) IL236233A (enExample)
IN (2) IN2015DN00334A (enExample)
MX (2) MX359615B (enExample)
NZ (2) NZ703949A (enExample)
RU (2) RU2653054C2 (enExample)
SG (3) SG10201703253XA (enExample)
WO (2) WO2013192225A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355669B1 (en) * 2000-08-10 2011-09-28 Cold Spring Harbor Laboratory Augmented cognitive training
US9175010B2 (en) 2012-06-18 2015-11-03 Dart Neuroscience (Cayman) Ltd. Therapeutic thiophene-, furan-, and pyridine-fused azolopyrimidin-5-(6H)-ones
JP6396229B2 (ja) * 2014-01-27 2018-09-26 株式会社ポーラファルマ 使用時泡状を呈する外用医薬組成物
JP6396230B2 (ja) * 2014-01-27 2018-09-26 株式会社ポーラファルマ 使用時泡状を呈する外用医薬組成物
JP6396231B2 (ja) * 2014-01-27 2018-09-26 株式会社ポーラファルマ 使用時泡状を呈する外用医薬組成物
GB201406486D0 (en) * 2014-04-10 2014-05-28 Redx Pharma Ltd Antibacterial compounds
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
WO2017046603A1 (en) * 2015-09-18 2017-03-23 Redx Pharma Plc Antibacterial compounds and new uses thereof
TWI609870B (zh) 2016-02-12 2018-01-01 美國禮來大藥廠 Pde1抑制劑
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
JOP20170164A1 (ar) 2016-08-25 2019-01-30 Lilly Co Eli مشتق ترايازولو بيرازينون مفيد كمثبط لـ pde1 بشري
EP3529250B1 (en) 2016-10-18 2023-12-06 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors
WO2018078038A1 (en) 2016-10-28 2018-05-03 H. Lundbeck A/S Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
CA3041595A1 (en) 2016-10-28 2018-05-03 H. Lundbeck A/S Combination treatments comprising administration of imidazopyrazinones
WO2018125810A1 (en) 2016-12-28 2018-07-05 Dart Neuroscience, Llc Substituted pyrazolopyrimidinone compounds as pde2 inhibitors
BR112019013388A2 (pt) * 2016-12-30 2020-03-03 Frequency Therapeutics, Inc. Compostos de 1h-pirrol-2,5-diona e métodos de uso dos mesmos para induzir a autorrenovação de células de suporte tronco/progenitoras
US10919898B2 (en) * 2017-02-23 2021-02-16 Boehringer Ingelheim International Gmbh Medical use of compound III
AR112457A1 (es) 2017-08-02 2019-10-30 Lilly Co Eli Derivados de [1,2,4]triazolo[4,3-a]pirazin-6(5h)-ona
AR112346A1 (es) * 2017-08-10 2019-10-16 Lilly Co Eli Derivados de [1,2,4]triazolo
MX2020005447A (es) 2017-11-27 2020-12-03 Dart Neuroscience Llc Compuestos de furanopirimidina sustituida como inhibidores de pde1.
CN112334475B (zh) 2018-04-13 2024-10-29 癌症研究技术有限公司 Bcl6抑制剂
GB2575490A (en) * 2018-07-12 2020-01-15 Recordati Ind Chimica E Farmaceutica Spa P2X3 receptor antagonists
WO2020146384A1 (en) 2019-01-07 2020-07-16 Intra-Cellular Therapies, Inc. Organic compounds
EP4017858A4 (en) * 2019-08-22 2023-09-27 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
GB201914860D0 (en) * 2019-10-14 2019-11-27 Cancer Research Tech Ltd Inhibitor compounds
CN112778311B (zh) * 2019-11-01 2024-06-04 上海翰森生物医药科技有限公司 含氮并环类衍生物抑制剂、其制备方法和应用
EP4389746A3 (en) * 2022-12-21 2024-07-03 Recordati Industria Chimica E Farmaceutica SPA P2x3 receptor antagonists
WO2025024543A1 (en) * 2023-07-24 2025-01-30 Bpgbio, Inc. Tricyclic ube2k modulators and methods for their use

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0217748A2 (en) * 1985-09-30 1987-04-08 Ciba-Geigy Ag 2-Substituted-e-fused-[1,2,4,]triazolo-[1,5-c]pyrimidines pharmaceutical compositions and uses thereof
US5128338A (en) * 1990-03-09 1992-07-07 Adir Et Compagnie Imidazo [1,2-c] quinazoline compounds
RU2258705C2 (ru) * 1999-07-27 2005-08-20 Алмираль Продесфарма С.А. ПРОИЗВОДНЫЕ 8-ФЕНИЛ-6,9-ДИГИДРО[1,2,4]-ТРИАЗОЛО[3,4-i]ПУРИН-5-ОНА, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ
WO2008118414A1 (en) * 2007-03-28 2008-10-02 Merck & Co., Inc. Substituted pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine derivatives as cannabinoid-1 receptor modulators
WO2010098839A1 (en) * 2009-02-25 2010-09-02 Intra-Cellular Therapies, Inc. Pde 1 inhibitors for ophthalmic disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3046366A1 (de) 1980-12-09 1982-07-08 Bayer Ag, 5090 Leverkusen Tricyclische cytosinderivate zur verwendung in arzneimitteln und verfahren zu ihrer herstellung
DE3146599A1 (de) 1981-11-25 1983-07-07 Basf Ag, 6700 Ludwigshafen Neue triazolochinazoline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
EP0181282A1 (de) 1984-10-01 1986-05-14 Ciba-Geigy Ag Triazolochinazolinverbindungen
JPS62135475A (ja) * 1985-09-30 1987-06-18 チバ−ガイギ−　アクチエンゲゼルシヤフト ２−置換−ｅ−融合−〔１，２，４〕トリアゾロ−〔１，５−Ｃ〕ピリミジン
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1999038504A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
DE10012373A1 (de) * 2000-03-14 2001-09-20 Dresden Arzneimittel Verwendung von Pyrido[3,2-e]-pyrazinonen als Inhibitoren der Phosphodiesterase 5 zur Therapie von erektiler Dysfunktion
EP1355669B1 (en) 2000-08-10 2011-09-28 Cold Spring Harbor Laboratory Augmented cognitive training
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
US8153646B2 (en) 2000-08-10 2012-04-10 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
FR2897061B1 (fr) * 2006-02-03 2010-09-03 Sanofi Aventis Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique.
CA2651519A1 (en) * 2006-06-06 2007-12-13 Intra-Cellular Therapies, Inc. Organic compounds
CA2684879A1 (en) 2007-05-15 2008-11-27 Helicon Therapeutics, Inc. Methods of identifying genes involved in memory formation using small interfering rna (sirna)
WO2009042432A1 (en) 2007-09-26 2009-04-02 Ge Healthcare Bioscience Bioprocess Corp. Three dimensional disposable bioreactor
CN104370922A (zh) 2007-12-06 2015-02-25 武田药品工业株式会社 有机化合物
EP2219646A4 (en) 2007-12-21 2010-12-22 Univ Rochester PROCESS FOR EXTENDING THE LIFE OF EUKARYOTIC ORGANISMS
SG171775A1 (en) 2008-12-06 2011-07-28 Intra Cellular Therapies Inc Organic compounds
EP2367431B1 (en) * 2008-12-06 2015-08-05 Intra-Cellular Therapies, Inc. Organic compounds
WO2010132127A1 (en) 2009-05-13 2010-11-18 Intra-Cellular Therapies, Inc. Organic compounds
US9763948B2 (en) 2010-05-31 2017-09-19 Intra-Cellular Therapies, Inc. PDE1 inhibitory compounds and methods
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
WO2011153136A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
US9371327B2 (en) 2010-05-31 2016-06-21 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
JP6051210B2 (ja) 2011-06-10 2016-12-27 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
US9175010B2 (en) * 2012-06-18 2015-11-03 Dart Neuroscience (Cayman) Ltd. Therapeutic thiophene-, furan-, and pyridine-fused azolopyrimidin-5-(6H)-ones

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0217748A2 (en) * 1985-09-30 1987-04-08 Ciba-Geigy Ag 2-Substituted-e-fused-[1,2,4,]triazolo-[1,5-c]pyrimidines pharmaceutical compositions and uses thereof
US5128338A (en) * 1990-03-09 1992-07-07 Adir Et Compagnie Imidazo [1,2-c] quinazoline compounds
RU2258705C2 (ru) * 1999-07-27 2005-08-20 Алмираль Продесфарма С.А. ПРОИЗВОДНЫЕ 8-ФЕНИЛ-6,9-ДИГИДРО[1,2,4]-ТРИАЗОЛО[3,4-i]ПУРИН-5-ОНА, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ
WO2008118414A1 (en) * 2007-03-28 2008-10-02 Merck & Co., Inc. Substituted pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine derivatives as cannabinoid-1 receptor modulators
WO2010098839A1 (en) * 2009-02-25 2010-09-02 Intra-Cellular Therapies, Inc. Pde 1 inhibitors for ophthalmic disorders

Also Published As

Publication number Publication date
WO2013192225A1 (en) 2013-12-27
EP3489238A1 (en) 2019-05-29
CN104583213B (zh) 2018-10-26
SG10201703253XA (en) 2017-06-29
ES2904267T3 (es) 2022-04-04
BR112014031730B1 (pt) 2023-05-16
US10376514B2 (en) 2019-08-13
AU2013277298A1 (en) 2015-02-05
AU2017272245B2 (en) 2019-08-29
AU2013277298B2 (en) 2017-09-07
US20190046535A1 (en) 2019-02-14
IL236232A0 (en) 2015-02-01
KR20150063030A (ko) 2015-06-08
US20160031901A1 (en) 2016-02-04
IL236232A (en) 2016-10-31
MX359615B (es) 2018-10-03
MX357320B (es) 2018-07-04
IN2015DN00335A (enExample) 2015-06-12
US9175010B2 (en) 2015-11-03
US9499562B2 (en) 2016-11-22
IL236233A0 (en) 2015-02-01
US10105367B2 (en) 2018-10-23
US20170209459A1 (en) 2017-07-27
HK1208024A1 (en) 2016-02-19
DK2861603T3 (en) 2019-03-04
JP2015526394A (ja) 2015-09-10
EP2861605B1 (en) 2017-05-03
CA2877149C (en) 2021-01-19
IL236233A (en) 2016-10-31
US20160075719A1 (en) 2016-03-17
EP3489238B1 (en) 2021-10-13
CN104583217A (zh) 2015-04-29
SG11201408397SA (en) 2015-01-29
RU2659779C2 (ru) 2018-07-04
CN104583217B (zh) 2017-11-17
MX2014015740A (es) 2015-11-06
EP3489238B8 (en) 2022-02-16
EP2861603A1 (en) 2015-04-22
JP2015526395A (ja) 2015-09-10
AU2013277294B2 (en) 2017-04-13
HK1208023A1 (en) 2016-02-19
CN104583213A (zh) 2015-04-29
IN2015DN00334A (enExample) 2015-06-12
RU2015100209A (ru) 2016-08-10
US20170182052A1 (en) 2017-06-29
US9533996B2 (en) 2017-01-03
US9284335B2 (en) 2016-03-15
BR112014031731B1 (pt) 2022-12-06
ES2715325T3 (es) 2019-06-03
CA2877149A1 (en) 2013-12-27
EP2861605A1 (en) 2015-04-22
EP2861605A4 (en) 2016-01-13
US20150158885A1 (en) 2015-06-11
WO2013192229A8 (en) 2015-09-03
EP2861603A4 (en) 2015-11-11
DK3489238T3 (da) 2022-01-10
AU2013277294C1 (en) 2018-02-08
AU2013277294A1 (en) 2015-02-05
SG11201408395WA (en) 2015-01-29
RU2015100213A (ru) 2016-08-10
US10092575B2 (en) 2018-10-09
BR112014031730A2 (pt) 2017-06-27
BR112014031731A2 (pt) 2017-06-27
MX2014015737A (es) 2015-09-16
US20130338139A1 (en) 2013-12-19
NZ703950A (en) 2016-10-28
AU2017272245A1 (en) 2018-01-04
KR20150063028A (ko) 2015-06-08
NZ703949A (en) 2016-10-28
CA2877146C (en) 2020-10-20
WO2013192229A1 (en) 2013-12-27
JP6129960B2 (ja) 2017-05-17
CA2877146A1 (en) 2013-12-27
JP6240180B2 (ja) 2017-11-29
KR102087756B1 (ko) 2020-03-12
KR102191816B1 (ko) 2020-12-17
EP2861603B1 (en) 2018-12-19

Similar Documents

Publication Publication Date Title
RU2653054C2 (ru) Замещенные соединения пиридин азолопиримидин-5-(6н)-она
JP6420400B2 (ja) 置換ピリジンアゾロピリミジン−５−（６ｈ）−オン化合物
HK40006641A (en) Pharmaceutical compositions of 6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one and [1,2,4]triazolo[1,5-c]pteridin-5(6h)-one derivatives as pde1 inhibitors for treating e.g. neurological disorders
HK40006641B (en) Pharmaceutical compositions of 6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one and [1,2,4]triazolo[1,5-c]pteridin-5(6h)-one derivatives as pde1 inhibitors for treating e.g. neurological disorders
HK1208023B (en) 6-benzyl-6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c] pyrimidin-5-one and 6-benzyl-[1,2,4]triazolo[1,5-c] pteridin-5(6h)-one derivatives as pde1 inhibitors for treating e.g. neurological disorders
HK1208024B (en) 6-benzyl-6h-thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one derivatives as phosphodiesterase-1 (pde-1) inhibitors for the treatment of e.g. neurological, cognitive and cardiovascular disorders